# New Sarcoma clinical trials: 170 posted since Nov 2024

Updated November 6, 2026.

170 clinical studies in sarcoma were first posted on ClinicalTrials.gov from November 12, 2024 to November 6, 2026; 34 have an industry sponsor and 140 are recruiting or about to. The newest, NCT07920835, was posted on November 6, 2026: A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging (Hexin (Suzhou) Pharmaceutical Technology Co., Ltd).

## The full list

New Sarcoma clinical trials: 170 rows for $8.50, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 6 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/sarcoma

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 170
- Industry sponsored: 34
- Recruiting or not yet: 140
- Latest posted: November 6, 2026

## Newest trials

The newest 100 of 170, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07920835 | A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging | Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | Phase 2 | Recruiting | Soft Tissue Sarcoma | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920835) |
| November 6, 2026 | NCT07920822 | Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors | Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | Phase 1 | Enrolling by invitation | Soft Tissue Sarcoma, Non-small Cell Lung Cancer | 12 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920822) |
| November 5, 2026 | NCT07917949 | Zemetostat With Anlotinib in Patients With Recurrent/Metastatic Head and Neck Soft Tissue Sarcoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 | Recruiting | Soft Tissue Sarcoma | 34 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917949) |
| October 23, 2026 | NCT07893041 | Exercise Rehabilitation to Improve Long-term Outcomes in Sarcoma Survivors. | Curtin University | Not applicable | Completed | Sarcoma, Sarcoma of Bone and Connective Tissue, Sarcoma of Soft Tissue, Sarcoma of Bone | 25 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893041) |
| October 22, 2026 | NCT07888114 | Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities | Beijing Tongren Hospital | Phase 1 | Recruiting | Soft Tissue Sarcoma | 16 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888114) |
| October 20, 2026 | NCT07884487 | Surgical Margin Assessment Using Intra-operative High-resolution PET/CT in Patients With Cancers Referred to Surgical Resection, an... | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Not applicable | Active not recruiting | Breast Cancer, Head and Neck Cancers, Lung Cancer, Sarcoma, Liver Metastases From Colorectal Cancer, Gastro Intestinal... | 250 | Belgium | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884487) |
| October 15, 2026 | NCT07874828 | PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Sarcoma,Soft Tissue | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874828) |
| October 8, 2026 | NCT07864870 | Sarcoma Care Adherence and Survival in Strasbourg | University Hospital, Strasbourg, France | Observational | Recruiting | Soft Tissue Sarcoma (STS) | 900 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864870) |
| October 6, 2026 | NCT07861217 | Paediatric Sarcoma, Hybrid Imaging & FAPI - Raising the Diagnostic Standard for Paediatric Sarcoma Patients, Combining Novel Radiotracer... | Copenhagen University Hospital, Rigshospitalet | Phase 2 | Not yet recruiting | Sarcoma | 40 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861217) |
| September 29, 2026 | NCT07847268 | A First-in-Human Study of ¹⁷⁷Lu-HX02 in Sarcoma Patients | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Observational | Completed | Sarcoma | 9 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847268) |
| September 25, 2026 | NCT07842276 | Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Soft Tissue Sarcoma (STS), Utidelone, Doxorubicin | 49 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07842276) |
| September 16, 2026 | NCT07822204 | Molecular and Clinical Studies of Bone and Soft Tissue Tumors | Karolinska Institutet | Observational | Recruiting | Bone and Soft Tissue Tumors | 50,000 | Sweden | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822204) |
| September 10, 2026 | NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | Advenchen Pharmaceuticals, LLC. | Phase 1/2 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma | 138 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811297) |
| September 10, 2026 | NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | Advenchen Pharmaceuticals, LLC. | Phase 1/2 | Not yet recruiting | Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms | 138 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811232) |
| September 3, 2026 | NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients. | Gustave Roussy, Cancer Campus, Grand Paris | Phase 4 | Not yet recruiting | Elderly, Breast Cancer, Lung Cancer, Prostate Cancer, Colon Cancer, Kidney Cancer, Sarcoma | 794 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802847) |
| September 3, 2026 | NCT07801222 | A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft... | SOTIO Biotech a.s. | Phase 1/2 | Not yet recruiting | Osteosarcoma Metastatic, Soft Tissue Sarcoma (STS), Osteosarcoma, Advanced | 70 | Moldova | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801222) |
| August 25, 2026 | NCT07785882 | Sarcoma and Intra-infusion Exercise for Better Outcomes | Kira Bloomquist | Not applicable | Not yet recruiting | Sarcoma | 16 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07785882) |
| August 25, 2026 | NCT07783620 | Treatment of Stage IV Cancer Patients With Multiple Patient-specific Mutated Cell Surface Proteins With Chimeric Antibodies | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 1 | Not yet recruiting | Soft Tissue Cancer | 16 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783620) |
| August 7, 2026 | NCT07751380 | Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma | University College, London | Phase 1 | Recruiting | Sarcoma | 12 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751380) |
| August 3, 2026 | NCT07741877 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma | Iovance Biotherapeutics, Inc. | Phase 2 | Recruiting | Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)... | 80 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741877) |
| July 29, 2026 | NCT07734116 | A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma. | Ono Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Pediatric Malignant Solid Tumor and Epithelioid Sarcoma | 50 | Japan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734116) |
| July 27, 2026 | NCT07729059 | "Exercise Intervention to Increase Physical Activity in Young Sarcoma Survivors (Sport Ist Herzenssache)" | Universität Duisburg-Essen | Not applicable | Not yet recruiting | Bone Sarcoma, Soft Tissue Sarcoma (STS) | 46 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729059) |
| July 24, 2026 | NCT07725380 | Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma | H. Lee Moffitt Cancer Center and Research Institute | Phase 1/2 | Recruiting | Sarcoma, Osteosarcoma | 74 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07725380) |
| July 15, 2026 | NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors | SHY Therapeutics | Phase 1 | Recruiting | Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric... | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705334) |
| June 30, 2026 | NCT07675967 | Clonal Hematopoiesis Chemotherapy and Radiation Effects Study | Dana-Farber Cancer Institute | Observational | Recruiting | Lung Cancer (Diagnosis), Osteochondroma, Spitz Nevus, Solid Cancers, Breast Cancer, Gastric (Stomach) Cancer... | 5,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07675967) |
| June 23, 2026 | NCT07662239 | Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention | Dana-Farber Cancer Institute | Not applicable | Recruiting | Sarcoma, Bone Sarcoma, Soft Tissue Sarcoma (STS) | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662239) |
| June 22, 2026 | NCT07658768 | Pilot Study of TumorGlow for Intraoperative Molecular Imaging of Sarcoma Metastases to the Lungs in Pediatric Patients | Abramson Cancer Center at Penn Medicine | Early phase 1 | Recruiting | Sarcoma Metastatic | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658768) |
| June 16, 2026 | NCT07651020 | The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Observational | Completed | Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma, Head and Neck Cancers, Glioblastoma, Colorectal Cancer... | 1 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07651020) |
| June 16, 2026 | NCT07650838 | OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Soft Tissue Sarcoma (STS) | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07650838) |
| June 16, 2026 | NCT07650656 | Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial | City of Hope Medical Center | Phase 2 | Recruiting | High Grade Sarcoma, Sarcoma | 22 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07650656) |
| June 15, 2026 | NCT07648069 | Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma | Sun Yat-sen University | Phase 1 | Recruiting | Soft Tissue Sarcoma (STS), Osteosarcoma | 16 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648069) |
| June 11, 2026 | NCT07642375 | Study of the Impact of Digital Health Interventions on Symptom & Side-Effect Management in Metastatic Sarcoma Patients | CareAcross | Not applicable | Recruiting | Advanced Sarcoma, Metastatic Sarcoma | 108 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642375) |
| June 5, 2026 | NCT07630961 | Phase I Study of JFI447 \[68Ga\]Ga-DFC413 and Comparison to FFG233 \[68Ga\]Ga-NNS309 in Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer... | 66 | Denmark, Japan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630961) |
| June 5, 2026 | NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | University of California, Irvine | Early phase 1 | Recruiting | Adenocarcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Ductal Carcinoma... | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07628634) |
| May 29, 2026 | NCT07614620 | Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor... | Institut Bergonié | Not applicable | Recruiting | Sarcoma, Germ Cell Tumor of Testis, Ovarian Tumor, Breast Cancer | 70 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614620) |
| May 28, 2026 | NCT07612098 | Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Soft Tissue Sarcoma (STS) | 274 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612098) |
| May 27, 2026 | NCT07609329 | Preoperative Immunonutrition in Patients With Bone and Soft Tissue Sarcomas | St. Anne's University Hospital Brno, Czech Republic | Not applicable | Recruiting | Bone Sarcoma, Soft Tissue Sarcoma, Sarcopenia, Malnutrition, Postoperative Complications | 100 | Czechia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609329) |
| May 22, 2026 | NCT07602777 | A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) | GlaxoSmithKline | Phase 1/2 | Recruiting | Sarcoma | 64 | Canada, France, Israel, Japan, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602777) |
| May 22, 2026 | NCT07602049 | Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma | Sun Yat-sen University | Phase 2 | Recruiting | Soft Tissue Sarcoma (STS), Osteosarcoma | 57 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602049) |
| May 8, 2026 | NCT07575724 | Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Not yet recruiting | Primary, Sarcoma | 3,300 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575724) |
| April 27, 2026 | NCT07553260 | Effectiveness of 0.9% Normal Saline Soaking in Managing Acute Radiation Dermatitis | King Hussein Cancer Center | Not applicable | Not yet recruiting | Acute Radiation Dermatitis, Head and Neck Cancer (H&N), Sarcomas | 150 | Jordan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553260) |
| April 27, 2026 | NCT07552467 | Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Observational | Recruiting | Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma, Head and Neck Tumors, Glioblastoma, Colorectal Cancer, Melanoma | 26 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552467) |
| April 16, 2026 | NCT07532668 | Multicentre Retrospective Cohort Study of Palliative Care Pathways in Patients Who Died From Sarcoma | Centre Leon Berard | Observational | Completed | Sarcoma | 207 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532668) |
| April 14, 2026 | NCT07528079 | Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors | Shanghai Jiao Tong University School of Medicine | Not applicable | Enrolling by invitation | Soft Tissue Sarcoma, Child | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07528079) |
| April 8, 2026 | NCT07516353 | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults | Dana-Farber Cancer Institute | Not applicable | Not yet recruiting | Sarcoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Acute Myeloid Leukemia, Aml, ALL, Medulloblastoma, Acute... | 143 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516353) |
| April 7, 2026 | NCT07514819 | Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma | St. Jude Children's Research Hospital | Not applicable | Recruiting | Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, Hodgkin Lymphoma, Bone Tumor, Soft Tissue Sarcoma | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514819) |
| April 2, 2026 | NCT07507773 | Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall | Centre Oscar Lambret | Phase 2 | Recruiting | Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma of the Trunk and Extremities, Soft... | 135 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07507773) |
| April 1, 2026 | NCT07505732 | Information-providing Chatbot | The Hong Kong Polytechnic University | Not applicable | Not yet recruiting | Sarcoma | 78 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07505732) |
| March 31, 2026 | NCT07502885 | Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients | St. Jude Children's Research Hospital | Observational | Recruiting | Sarcoma, Bone, Sarcoma, Soft Tissue, Gait Disorder | 300 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502885) |
| March 31, 2026 | NCT07502716 | Compassionate Use of Ubamatamab | Regeneron Pharmaceuticals | Not applicable | Available | Renal Medullary Carcinoma (RMC), Epithelioid Sarcoma | Not listed |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502716) |
| March 30, 2026 | NCT07501026 | Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Recruiting | Sarcoma | 22 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07501026) |
| March 24, 2026 | NCT07491783 | Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial | Sichuan Enray Pharmaceutical Sciences Company | Phase 2 | Not yet recruiting | HNSCC, Soft Tissue Cancer | 52 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07491783) |
| March 23, 2026 | NCT07487870 | Radiographic Evaluation of Tumor Biology During Neoadjuvant Radiotherapy for Sarcoma | Andrew Frankart | Not applicable | Not yet recruiting | Sarcoma | 5 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07487870) |
| March 13, 2026 | NCT07470008 | Prospective Registry of Histotripsy for Soft Tissue Tumors | University of California, San Francisco | Observational | Enrolling by invitation | Soft Tissue Neoplasm, Soft Tissue Cancer, Soft Tissue Lesion | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07470008) |
| March 10, 2026 | NCT07460986 | A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma. | MedSIR | Phase 1/2 | Recruiting | Soft Tissue Sarcoma (STS) | 278 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07460986) |
| March 9, 2026 | NCT07459283 | The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors | FindCure Biosciences (ZhongShan) Co., Ltd. | Early phase 1 | Recruiting | Maligant Solid Tumor, Head & Neck Cancer, Thyroid Cancer, Lung Cancer - Non Small Cell Squamous, Breast Cancer, Sarcoma | 10 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07459283) |
| March 9, 2026 | NCT07457775 | Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Not yet recruiting | Soft Tissue Sarcoma (Excluding GIST) | 24 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07457775) |
| March 3, 2026 | NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | University of California, Irvine | Phase 2 | Recruiting | Breast Cancer, Sarcoma, Gastric (Stomach) Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer... | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07447050) |
| March 3, 2026 | NCT07444619 | A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With... | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Soft Tissue Sarcomas | 18 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444619) |
| February 27, 2026 | NCT07436364 | Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy | Thomas Jefferson University | Early phase 1 | Recruiting | Soft Tissue Sarcoma | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07436364) |
| February 25, 2026 | NCT07432932 | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients | Royal Marsden NHS Foundation Trust | Observational | Recruiting | Sarcoma, Sarcoma, Leiomyo-, Adult, Sarcoma, Synovial, Adult, Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult, Soft... | 800 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432932) |
| February 13, 2026 | NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer... | 83 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410676) |
| February 12, 2026 | NCT07406087 | Navigation Intervention for Adolescent and Young Adult Cancer Survivors | Kaiser Permanente | Not applicable | Recruiting | Breast Cancer, Ovarian Cancer, Cervical Cancer, Testicular Cancer, Colon Rectal Cancer, Melanoma (Skin Cancer)... | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07406087) |
| February 11, 2026 | NCT07402577 | Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot Feasibility Study | Roswell Park Cancer Institute | Observational | Recruiting | Sarcoma, Childhood Sarcoma of Soft Tissue | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07402577) |
| February 10, 2026 | NCT07401355 | Improved Management of Soft Tissue Sarcomas Patients With an Optimized and Innovative Sorting Technology for Circulating Tumor Cells | Centre Leon Berard | Not applicable | Not yet recruiting | Diagnosis of Soft Tissue Sarcoma (STS) | 100 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07401355) |
| February 9, 2026 | NCT07396116 | Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not applicable | Not yet recruiting | Soft Tissue Sarcoma (STS), Retroperitoneal Sarcoma, Immunotherapy, Radiotherapy Side Effect, Ultra-hypofractionated... | 28 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07396116) |
| February 5, 2026 | NCT07389525 | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study | Indiana University | Early phase 1 | Not yet recruiting | Gastrointestinal Neoplasms, Genitourinary Cancer, Thoracic Cancer, Sarcoma, Melanoma | 80 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07389525) |
| January 30, 2026 | NCT07377747 | Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma | Australia and New Zealand Sarcoma Association | Observational | Recruiting | Retroperitoneal Liposarcoma | 100 | Australia, Belgium, Brazil, Canada, France, Netherlands, Poland, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07377747) |
| January 29, 2026 | NCT07374848 | Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors | Zai Lab (Shanghai) Co., Ltd. | Phase 1 | Recruiting | Solid Tumors, Sarcomas | 180 | China, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07374848) |
| January 22, 2026 | NCT07359911 | Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patients | University of Miami | Not applicable | Recruiting | Sarcoma | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07359911) |
| January 22, 2026 | NCT07359053 | MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma | Shanghai 6th People's Hospital | Phase 2 | Recruiting | Sarcoma | 46 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07359053) |
| January 15, 2026 | NCT07342322 | A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated... | First Affiliated Hospital of Guangxi Medical University | Phase 2 | Not yet recruiting | Soft Tissue Sarcoma (STS) | 25 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07342322) |
| December 22, 2025 | NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors | Baylor College of Medicine | Phase 1 | Withdrawn | Lymphoma, Myeloma, Solid Tumors, Sarcoma, Kidney Cancer | 0 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297160) |
| December 18, 2025 | NCT07291297 | Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic... | Wake Forest University Health Sciences | Phase 2 | Recruiting | Sarcoma Metastatic, Sarcoma, Soft Tissue | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07291297) |
| December 16, 2025 | NCT07283731 | Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Phase 2, Zanzalintinib, Pembrolizumab, Advanced/Metastatic, Soft-Tissue Sarcoma | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283731) |
| December 11, 2025 | NCT07276867 | Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee... | National Cancer Institute, Egypt | Not applicable | Recruiting | Intrathecal, Dexmedetomidine, Fentanyl, Bupivacaine, Spinal Anesthesia, Above Knee Amputation, Sarcomas, Lower Extremity | 58 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07276867) |
| December 3, 2025 | NCT07261631 | Phase I Study of \[177Lu\]Lu-DFC413 in Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple... | 180 | Canada, Denmark, France, Germany, Israel, Singapore, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07261631) |
| November 26, 2025 | NCT07250334 | Prospective Phase I/II Study Evaluating the Safety and Efficacy of Preoperative Carbon Ion Radiotherapy in Patients With Soft Tissue... | Yonsei University | Not applicable | Not yet recruiting | Soft Tissue Sarcoma | 60 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07250334) |
| November 24, 2025 | NCT07243626 | Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Recruiting | Soft Tissue Sarcoma | 25 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07243626) |
| November 14, 2025 | NCT07229313 | A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors | Kivu Bioscience Inc. | Phase 1 | Recruiting | Advance Solid Tumors | 76 | Australia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07229313) |
| November 13, 2025 | NCT07227961 | Activation Sarcoma: PROMIS and Mobility Evaluation in Sarcoma Patients | University of Calgary | Observational | Recruiting | Sarcoma, Giant Cell Tumor of Bone | 800 | Canada, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227961) |
| October 30, 2025 | NCT07222735 | Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas | St. Jude Children's Research Hospital | Phase 1 | Recruiting | Sarcoma, Childhood Osteosarcoma, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma | 42 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222735) |
| October 14, 2025 | NCT07215832 | Karyopharm Expanded Access Program for Selinexor | Karyopharm Therapeutics Inc | Not applicable | Available | Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma, Peripheral T-cell Lymphoma... | Not listed |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07215832) |
| October 10, 2025 | NCT07215728 | Machine Learning Applied to EHRs Data of Patients With Sarcoma | University of Milano Bicocca | Observational | Completed | Sarcoma, Osteosarcoma, Ewing Sarcoma | 700 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07215728) |
| October 3, 2025 | NCT07205185 | A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for... | Fudan University | Phase 2 | Not yet recruiting | Soft Tissue Sarcoma (STS) | 46 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07205185) |
| September 25, 2025 | NCT07192068 | Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene. | UNICANCER | Phase 2 | Recruiting | Non-Small Cell Lung Cancer, Sarcoma, Head &Amp; Neck Cancer, Colorectal Carcinoma, Endometrial | 105 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07192068) |
| September 24, 2025 | NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | Radiopharm Theranostics, Ltd | Phase 1/2 | Recruiting | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer... | 61 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189871) |
| September 15, 2025 | NCT07173972 | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. | Oslo University Hospital | Phase 2 | Recruiting | Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma of the Trunk and Extremities, Synovial... | 40 | Norway | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07173972) |
| September 11, 2025 | NCT07169344 | Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma | Oslo University Hospital | Phase 2 | Recruiting | Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma of the Trunk and Extremities... | 110 | Norway | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07169344) |
| September 5, 2025 | NCT07156565 | Actinium Therapy for Late-stage Aggressive Sarcomas | Ratio Therapeutics, Inc. | Phase 1 | Active not recruiting | Advanced Soft Tissue Sarcoma | 48 | Canada, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07156565) |
| August 29, 2025 | NCT07148193 | Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+) | Technische Universität Dresden | Observational | Recruiting | Sarcoma, Survivorship, Quality of Life (QOL), Medical Care | 1,600 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07148193) |
| August 24, 2025 | NCT07139990 | Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) | University of Texas Southwestern Medical Center | Phase 1 | Recruiting | Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer, Sarcoma,Soft Tissue... | 105 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07139990) |
| August 22, 2025 | NCT07136571 | Phase I Study of Safety and Feasibility of Transarterial Embolization of Incurable Hypervascular Pediatric Soft Tissue Sarcomas | University of Alabama at Birmingham | Not applicable | Withdrawn | Soft Tissue Sarcomas | 0 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07136571) |
| August 21, 2025 | NCT07134192 | Fluorescence-Guided Optimization of Sarcoma Margins | University of Aarhus | Not applicable | Recruiting | Soft Tissue Sarcoma of the Trunk and Extremities, Sarcoma | 90 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07134192) |
| August 19, 2025 | NCT07129317 | Pediatric Radiation Therapy Registry | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Observational | Recruiting | Sarcoma, Pediatric Brain Tumors | 5,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07129317) |
| August 15, 2025 | NCT07125183 | Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma | University of Colorado, Denver | Phase 2 | Recruiting | Sarcoma | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07125183) |
| August 15, 2025 | NCT07124000 | DESTINY-PANTUMOUR04 | AstraZeneca | Observational | Recruiting | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder... | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07124000) |
| August 12, 2025 | NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | Jonsson Comprehensive Cancer Center | Phase 1 | Active not recruiting | Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma... | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07118176) |
| August 8, 2025 | NCT07112989 | Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors | Istituto Ortopedico Rizzoli | Observational | Recruiting | Bone and Soft Tissue Tumors, Bone Metastases From Solid Tumors, Lung Metastases | 125 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07112989) |
| August 5, 2025 | NCT07104955 | Salutare One Referral Software Impact on Multi-Disciplinary Team (MDT) Meetings Effectiveness and Safety | Salutare Group Ltd. | Not applicable | Recruiting | Cancer (Solid Tumors), Sarcoma | 40 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07104955) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 5 | May 8, 2026 |
| M.D. Anderson Cancer Center | 4 | October 15, 2026 |
| Fudan University | 4 | October 3, 2025 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 3 | September 29, 2026 |
| Dana-Farber Cancer Institute | 3 | June 30, 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 3 | June 16, 2026 |
| Sun Yat-sen University | 3 | June 15, 2026 |
| University of California, Irvine | 3 | June 5, 2026 |
| St. Jude Children's Research Hospital | 3 | April 7, 2026 |
| University of Calgary | 3 | November 13, 2025 |
| University Health Network, Toronto | 3 | June 18, 2025 |
| Washington University School of Medicine | 3 | May 13, 2025 |
| Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | 2 | November 6, 2026 |
| Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2 | October 20, 2026 |
| Advenchen Pharmaceuticals, LLC. | 2 | September 10, 2026 |
| Novartis Pharmaceuticals | 2 | June 5, 2026 |
| Centre Leon Berard | 2 | April 16, 2026 |
| Essen Biotech | 2 | February 13, 2026 |
| Wake Forest University Health Sciences | 2 | December 18, 2025 |
| Oslo University Hospital | 2 | September 15, 2025 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 47 | October 23, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 40 | November 6, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 29 | October 8, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 27 | November 6, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 16 | September 10, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 9 | June 22, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 1 | September 3, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 1 | May 23, 2025 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 67 | October 15, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 36 | November 6, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 14 | October 8, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 13 | May 22, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 9 | August 7, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 7 | December 3, 2025 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 7 | August 8, 2025 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 6 | October 6, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 5 | July 29, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 5 | January 30, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 4 | October 20, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 4 | January 30, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 4 | April 24, 2025 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 3 | March 10, 2026 |
| [Sweden](https://specstream.ai/data/clinical-trials/country/sweden) | 2 | September 16, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 2 | May 22, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 2 | November 26, 2025 |
| [Norway](https://specstream.ai/data/clinical-trials/country/norway) | 2 | September 15, 2025 |
| [Moldova](https://specstream.ai/data/clinical-trials/country/moldova) | 1 | September 3, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 1 | June 11, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 1 | May 27, 2026 |
| [Jordan](https://specstream.ai/data/clinical-trials/country/jordan) | 1 | April 27, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 1 | January 30, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 1 | January 30, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 1 | December 11, 2025 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).